These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 15707388)

  • 21. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.
    Jukema JW; van Boven AJ; Groenemeijer B; Zwinderman AH; Reiber JH; Bruschke AV; Henneman JA; Molhoek GP; Bruin T; Jansen H; Gagné E; Hayden MR; Kastelein JJ
    Circulation; 1996 Oct; 94(8):1913-8. PubMed ID: 8873668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study.
    Nakagawa T; Kobayashi T; Awata N; Sato S; Reiber JH; Nakajima H; Toyama YN; Hiraoka H; Kato O; Kirino M; Kobayashi T; Takeda Y; Yachiku K; Iida M; Itoh T; Shibata N
    Int J Cardiol; 2004 Oct; 97(1):107-14. PubMed ID: 15336816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of CYP7A1 -278A>C polymorphism and the response of plasma triglyceride after dietary intervention in dyslipidemic patients.
    Barcelos AL; Chies R; Almeida SE; Fiegenbaum M; Schweigert ID; Chula FG; Rossetti ML; Silva CM
    Braz J Med Biol Res; 2009 Jun; 42(6):487-93. PubMed ID: 19448895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Association between cholesterol 7alpha-hydroxylase -204A/C gene polymorphism and endogenous hypertriglyceridemia in Chinese].
    Qiao Y; Liu R; Bai H; Liu Y; Li X; Tang CW; Liu BW
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):432-6. PubMed ID: 17680536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Association of 7alpha-hydroxylase gene polymorphism with levels of plasma lipids].
    Zhou B; Zhang SZ; Xiao CY; Zhang KL; Zhang L; Li GX; Li P; Liu HK; Zheng KQ
    Yi Chuan; 2004 May; 26(3):283-6. PubMed ID: 15640003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP7A1 A-278C polymorphism affects the response of plasma lipids after dietary cholesterol or cafestol interventions in humans.
    Hofman MK; Weggemans RM; Zock PL; Schouten EG; Katan MB; Princen HM
    J Nutr; 2004 Sep; 134(9):2200-4. PubMed ID: 15333704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholesterol 7alpha-hydrolase (CYP7A1) c.-278A>C promoter polymorphism in gallstone disease patients.
    Juzyszyn Z; Kurzawski M; Lener A; Modrzejewski A; Pawlik A; Droździk M
    Genet Test; 2008 Mar; 12(1):97-100. PubMed ID: 18307386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
    de Groot E; Jukema JW; van Boven AJ; Reiber JH; Zwinderman AH; Lie KI; Ackerstaff RA; Bruschke AV
    Am J Cardiol; 1995 Sep; 76(9):40C-46C. PubMed ID: 7572685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of common variants of ABCB1 and CYP7A1 genes in serum lipid levels and lipid-lowering efficacy of statin treatment: a meta-analysis.
    Li Q; Hong J; Wu J; Huang ZX; Li QJ; Yin RX; Lin QZ; Wang F
    J Clin Lipidol; 2014; 8(6):618-629. PubMed ID: 25499945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP7A1 gene polymorphism located in the 5' upstream region modifies the risk of coronary artery disease.
    Iwanicki T; Balcerzyk A; Niemiec P; Nowak T; Ochalska-Tyka A; Krauze J; Kosiorz-Gorczynska S; Grzeszczak W; Zak I
    Dis Markers; 2015; 2015():185969. PubMed ID: 25944972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
    Schoenhagen P; Tuzcu EM; Apperson-Hansen C; Wang C; Wolski K; Lin S; Sipahi I; Nicholls SJ; Magyar WA; Loyd A; Churchill T; Crowe T; Nissen SE
    Circulation; 2006 Jun; 113(24):2826-34. PubMed ID: 16769916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CETP (cholesteryl ester transfer protein) promoter -1337 C>T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia.
    Takata M; Inazu A; Katsuda S; Miwa K; Kawashiri MA; Nohara A; Higashikata T; Kobayashi J; Mabuchi H; Yamagishi M
    Clin Sci (Lond); 2006 Nov; 111(5):325-31. PubMed ID: 16822236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between the cholesterol ester transfer protein TaqIB polymorphism and the lipid-lowering effect of atorvastatin in patients with coronary atherosclerotic heart disease.
    Li J; Zhang L; Xie NZ; Deng B; Lv LX; Zheng LQ
    Genet Mol Res; 2014 Mar; 13(1):2140-8. PubMed ID: 24737438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
    Scartezini M; Hubbart C; Whittall RA; Cooper JA; Neil AH; Humphries SE
    Clin Sci (Lond); 2007 Dec; 113(11):435-41. PubMed ID: 17550346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interactions Between Regulatory Variants in CYP7A1 (Cholesterol 7α-Hydroxylase) Promoter and Enhancer Regions Regulate CYP7A1 Expression.
    Wang D; Hartmann K; Seweryn M; Sadee W
    Circ Genom Precis Med; 2018 Oct; 11(10):e002082. PubMed ID: 30354296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group.
    de Maat MP; Kastelein JJ; Jukema JW; Zwinderman AH; Jansen H; Groenemeier B; Bruschke AV; Kluft C
    Arterioscler Thromb Vasc Biol; 1998 Feb; 18(2):265-71. PubMed ID: 9484992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between CYP7A1 -204A>C polymorphism with gallbladder stone disease and serum lipid levels: a meta-analysis.
    Cai Q; Wang ZQ; Cai Q; Li C; Chen EZ; Jiang ZY
    Lipids Health Dis; 2014 Aug; 13():126. PubMed ID: 25103562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of cholesterol 7alpha-hydroxylase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol lowering.
    Hubacek JA; Bobkova D
    Mol Diagn Ther; 2006; 10(2):93-100. PubMed ID: 16669607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel functional polymorphism in the PECAM-1 gene (53G>A) is associated with progression of atherosclerosis in the LOCAT and REGRESS studies.
    Elrayess MA; Webb KE; Flavell DM; Syvänne M; Taskinen MR; Frick MH; Nieminen MS; Kesäniemi YA; Pasternack A; Jukema JW; Kastelein JJ; Zwinderman AH; Humphries SE
    Atherosclerosis; 2003 May; 168(1):131-8. PubMed ID: 12732396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.